Squamous Cell Carcinoma of the Head and Neck Clinical Trial
Malnutrition is currently a major factor of morbidity and mortality, which poses a major
public health problem in developing countries but also, albeit to a lesser degree and for
different reasons, for industrialized countries. It is recognized that in countries "of the
North", from 30 to 60% of hospitalized patients suffer from dénutrition.
In any case, it is covered by an imbalance between the contributions and needs; the two main
mechanisms are a delivery failure (fasting, ingesting difficulty ...) and / or increased
requirements (hypermetabolism ...). In cancer patients the Aero-Digestive Upper Airways
(VADS), this imbalance is even more pronounced than the two mechanisms exist and potentiate.
Patients included in this study are a population at risk, because of their therapeutic
containing at least radiotherapy. It is recognized that this form of therapy exposes dental
complications, mucous, saliva. These complications have a deleterious effect on the
nutritional status of patients.
The diagnosis, treatment and prevention of dénutritions have an important place in the
therapeutic strategies of this type of cancer because it is events whose incidence and
morbid consequences are high and for which there are appropriate nutritional treatments in
most cas. While the complete correction of malnutrition generally passes by the effective
etiological treatment of the causal pathology, therapeutic efficacy of the latter is often
conditioned by the nutritionnel state.
In addition to these concepts, investigators wants to study the benefits of a diet followed
during the irradiation phase of patients with head and neck cancers and New treaties. We
propose a randomized, phase III, open, multicenter, to evaluate the impact of a dietary
consultation at home on the life quality of patients with head and neck cancer including
first therapeutic sequence involves radiotherapy more or less aware. The duration of the
study is 24 months.
The main objective is to evaluate the impact of a dietary consultation at home on the life
quality of patients with head and neck cancer including first therapeutic sequence involves
a more or less sensitized radiotherapy.
n/a
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
| Recruiting |
NCT06236464 -
Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas
|
||
| Terminated |
NCT04659369 -
Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC
|
Phase 1 | |
| Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
| Recruiting |
NCT02572778 -
Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer
|
||
| Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
| Terminated |
NCT01488318 -
Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT00999700 -
Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin
|
Phase 3 | |
| Completed |
NCT02565758 -
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT02543476 -
SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
|
N/A | |
| Recruiting |
NCT03938012 -
Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell Carcinoma
|
||
| Terminated |
NCT02124850 -
A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab
|
Phase 1 | |
| Active, not recruiting |
NCT03313804 -
Priming Immunotherapy in Advanced Disease With Radiation
|
Phase 2 | |
| Recruiting |
NCT05208762 -
A Study of SGN-PDL1V in Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT04453046 -
Hemopurifier Plus Pembrolizumab in Head and Neck Cancer
|
N/A | |
| Completed |
NCT01758731 -
Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History
|
Phase 1 | |
| Completed |
NCT02473731 -
A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients
|
Phase 1 | |
| Completed |
NCT02022098 -
Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial
|
N/A | |
| Completed |
NCT01458392 -
Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
| Completed |
NCT02882308 -
Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.
|
Phase 2 |